Viral Conjunctivitis Pipeline Review, H1 2017 Featuring Adenovir Pharma, Marinomed Biotechnologie, NanoViricides, Panoptes Pharma, Shire & Starpharma - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Viral Conjunctivitis - Pipeline Review, H1 2017" report to their offering.

Viral Conjunctivitis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Viral Conjunctivitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Viral Conjunctivitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Viral Conjunctivitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 2, 1 and 5 respectively.

Viral Conjunctivitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

  1. Introduction
  2. Viral Conjunctivitis - Overview
  3. Viral Conjunctivitis - Therapeutics Development
  4. Pipeline Overview
  5. Pipeline by Companies
  6. Products under Development by Companies
  7. Viral Conjunctivitis - Therapeutics Assessment
  8. Assessment by Target
  9. Assessment by Mechanism of Action
  10. Assessment by Route of Administration
  11. Assessment by Molecule Type
  12. Viral Conjunctivitis - Companies Involved in Therapeutics Development
  • Adenovir Pharma AB
  • Marinomed Biotechnologie GmbH
  • NanoViricides Inc
  • Panoptes Pharma GesmbH
  • Shire Plc
  • Starpharma Holdings Ltd

For more information about this report visit http://www.researchandmarkets.com/research/rqdqjl/viral

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Infectious Diseases Drugs, Optical, Optical Disorders Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Infectious Diseases Drugs, Optical, Optical Disorders Drugs